Comparative Pharmacology
Head-to-head clinical analysis: ERY TAB versus ERYPED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERY TAB versus ERYPED.
ERY-TAB vs ERYPED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic